Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China - Scorecard - MDSpire
Advertisement
Nafamostat mesilate for anticoagulation in pediatric trauma patients undergoing extracorporeal membrane oxygenation: a two-center observational study in Northwest China
Clinical Scorecard: Use of Nafamostat Mesilate for Anticoagulation in Pediatric Trauma Patients Undergoing ECMO: An Observational Study Across Two Centers in Northwest China
At a Glance
Category
Detail
Condition
Pediatric trauma requiring ECMO support
Key Mechanisms
Nafamostat mesilate inhibits thrombin and coagulation factors, providing effective anticoagulation with reduced bleeding risk.
Target Population
Pediatric patients with severe trauma undergoing ECMO
Care Setting
Pediatric Intensive Care Units
Key Highlights
Nafamostat mesilate shows comparable anticoagulation efficacy to unfractionated heparin (UFH).
Patients on UFH had a higher incidence of new-onset active bleeding and circuit thrombosis.
Mandatory anticoagulant discontinuation was significantly higher in the UFH group due to bleeding.
Nafamostat mesilate may be preferable for patients at high risk of hemorrhage.
Guideline-Based Recommendations
Diagnosis
Assess the need for ECMO in pediatric trauma patients based on respiratory failure criteria.
Management
Consider nafamostat mesilate for anticoagulation in ECMO to reduce bleeding risks.
Monitoring & Follow-up
Regularly evaluate coagulation parameters and bleeding complications in patients receiving ECMO.
Risks
Monitor for active bleeding and thrombosis, especially in patients on UFH.
Patient & Prescribing Data
Pediatric patients hospitalized for severe trauma requiring ECMO support.
Nafamostat mesilate is effective in managing anticoagulation with a lower risk of complications compared to UFH.
Clinical Best Practices
Utilize nafamostat mesilate in high-risk pediatric trauma patients on ECMO.
Conduct thorough assessments of bleeding risks when selecting anticoagulants.
